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BACKGROUND: Prostate-specific antigen (PSA) screening has low specificity. Assessment of methylation status in body fluids may
complement PSA screening if the test has high specificity.
METHOD: The purpose of this study was to conduct a meta-analysis of the sensitivity and specificity for prostate cancer detection of
glutathione-s-transferase–p (GSTP1) methylation in body fluids (plasma, serum, whole blood, urine, ejaculate, and prostatic
secretions). We conducted a comprehensive literature search on Medline (Pubmed). We included studies if they met all four of the
following criteria: (1) measurement of DNA methylation in body fluids; (2) a case-control or case-only design; (3) publication in an
English journal; and (4) adult subjects. Reviewers conducted data extraction independently using a standardised protocol. Twenty-
two studies were finally included in this paper. Primer sequences and methylation method in each study were summarised and
evaluated using meta-analyses. This paper represents a unique cross-disciplinary approach to molecular epidemiology.
RESULTS: The pooled specificity of GSTP1 promoter methylation measured in plasma, serum, and urine samples from negative-biopsy
controls was 0.89 (95% CI, 0.80–0.95). Stratified analyses consistently showed a high specificity across different sample types and
methylation methods (include both primer sequences and location). The pooled sensitivity was 0.52 (95% CI, 0.40–0.64).
CONCLUSIONS: The pooled specificity of GSTP1 promoter methylation measures in plasma, serum, and urine was excellent and much
higher than the specificity of PSA. The sensitivity of GSTP1 was modest, no higher than that of PSA. These results suggest that
measurement of GSTP1 promoter methylation in plasma, serum, or urine samples may complement PSA screening for prostate
cancer diagnosis.
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Prostate cancer is the most common cancer in men and the second
leading cause of cancer-related death in both the United States and
Western Europe. With a sensitivity of 80%, prostate-specific
antigen (PSA) screening significantly increases the early diagnosis
of prostate cancer (Catalona, 1994). However, the specificity of
PSA screening is only 20% and may lead to many unnecessary
biopsies and overtreatment. A highly specific circulating bio-
marker (using plasma, serum, or urine samples) that complements
the traditional PSA test is therefore in great demand. A specific and
non-invasive test would allow patients to avoid the physical pain
and discomfort associated with biopsies, and avoid the adverse
effects and unnecessary medical spending resulting from over-
treatment. A blood draw is already essential for PSA screening and
urine samples are easy to obtain; thus, in conjunction with
measuring PSA levels, an additional measurement of plasma,
serum, or urinary biomarkers does not place any extra burden on
patients.
Gene promoter CpG island hypermethylation is one of the
earliest somatic genome alterations during the development of
several types of cancers. Studies have shown that glutathione-s-
transferase—p (GSTP1) promoter hypermethylation is the most
common somatic genome alteration during prostate cancer
development (Lee et al, 1994; Goessl, 2000; Kang et al, 2004). If
GSTP1 promoter hypermethylation can be detected in body fluids
and if it accurately predicts prostate cancer, then this measurement
has the potential to complement PSA screening. Research has
shown that the prostate, as well as circulating phagocytic cells that
have ingested prostate cancer cells, can release DNA into blood
circulation (Nakayama et al, 2004). DNA can also appear in urine,
ejaculates, and prostatic secretions after cells are shed into
prostatic ducts. Therefore, detection of methylation status in body
fluids (plasma, serum, whole blood, urine, ejaculates, and prostatic
secretion) may complement PSA screening if the test has high
specificity. Furthermore, although some studies have explored
whether GSTP1 promoter hypermethylation in body fluids is
associated with the patient’s pathological stage, Gleason score, or
PSA level, no meta-analysis has been carried out to summarise
these results.
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sThe purpose of this study was to conduct a meta-analysis on the
sensitivity and specificity of GSTP1 methylation in body fluids on
prostate cancer detection. We assessed the usefulness of several
types of body fluids, including whole blood, plasma, serum, buffy
coat, urine, ejaculates, and prostatic secretions. We also deter-
mined whether GSTP1 methylation was correlated with patholo-
gical stage, Gleason score, and/or PSA level among the cases.
MATERIALS AND METHODS
Study selection
We conducted a comprehensive literature search on Medline
(Pubmed) of articles published between 1966 and January 30, 2010.
We used the keywords ‘methylation’ and ‘prostate cancer’ in
conjunction with any of the following terms: ‘whole blood’,
‘plasma’, ‘serum’, ‘urine’, ‘ejaculate’, and ‘prostate secrete’.
Additional studies were found via the reference lists in the
identified articles.
We included the studies that met all four of the following
inclusion criteria: (1) measurement of DNA methylation in one of
the following body fluids—whole blood, plasma, serum, buffy coat,
urine, ejaculates, or prostate secretions; (2) a case-control or case-
only study; (3) published in an English language journal; and
(4) conducted in adults. We excluded studies that did not test
GSTP1 methylation in body fluids. We also excluded studies in
which men recently underwent a transurethral resection of the
prostate or brachytherapy, or took medications (e.g., Finasteride),
because these treatments or medications have the potential to
reduce PSA levels. The selection process for studies included in our
review is shown in Figure 1. Our search strategy and inclusion/
exclusion criteria resulted in a total of 22 articles that were
included in the systemic review (Suh et al, 2000; Cairns et al, 2001;
Goessl et al, 2001a,b; Jeronimo et al, 2002; Gonzalgo et al, 2003,
2004; Crocitto et al, 2004; Hoque et al, 2005; Papadopoulou et al,
2006; Rogers et al, 2006; Chuang et al, 2007; Reibenwein et al, 2007;
Roupret et al, 2007, 2008; Altimari et al, 2008; Bastian et al, 2008;
Bryzgunova et al, 2008; Ellinger et al, 2008; Woodson et al, 2008;
Sunami et al, 2009). The age range of subjects in the 22 studies was
40–74 years. Details of each study such as mean age of case and
control status are included in Supplementary Table 1.
As evaluating the specificity of the methylation test was the
major focus of this study, we rigorously classified our controls to
remove potential heterogeneity, thereby minimising selection bias.
It is well accepted that patients who are referred for biopsies
typically have elevated PSA levels, an abnormal digital rectal exam,
or related symptoms, and thus are completely different from
randomly selected healthy controls. Healthy controls are most
likely to introduce bias, resulting in a high specificity. Therefore,
among the studies included, we classified controls into two
categories: (1) patients who had negative biopsies (10 studies)
(Goessl et al, 2001a,b; Jeronimo et al, 2002; Gonzalgo et al, 2003;
Crocitto et al, 2004; Bastian et al, 2008; Ellinger et al, 2008;
Rossouw et al, 2008; Woodson et al, 2008; Payne et al, 2009) but
had other diseases, including benign prostatic hyperplasia, other
urologic symptoms (e.g., hematuria), or other types of cancers
(e.g., lung cancer or colon cancer); and (2) healthy controls
(9 studies) (Papadopoulou et al, 2006; Rogers et al, 2006;
Reibenwein et al, 2007; Roupret et al, 2007; Altimari et al, 2008;
Bryzgunova et al, 2008; Ellinger et al, 2008; Payne et al, 2009;
Sunami et al, 2009). As prostatic intraepithelial neoplasia (PIN)
was treated as a case in this study (see below), we excluded the data
using PIN as a control in two studies (Goessl et al, 2001b;
Woodson et al, 2008). We excluded Hoque et al (2005) from the
first category because some of their controls did not have negative
biopsies. Although we calculated the specificity separately for the
two types of controls, our conclusions were not based on the
results generated from healthy controls.
Biopsy-confirmed prostate cancer was treated as a case, except
for one study in which biopsy-confirmed PIN was treated as a case.
The timing of sample collection from cases varied widely. Some
samples were collected prior to biopsies, some after biopsies, some
after radical prostatectomy or surgery, and some after hormone
therapy. As removing the prostate may influence the likelihood of
cancer cells being released into circulation and because hormone
treatments may change gene methylation status, we also stratified
our analyses by treatment status when samples were collected
from cases.
For methylation measurements, we classified them as follows:
non-quantitative methylation-specific PCR (N-MSP), quantitative
MSP (Q-MSP), methylation-sensitive restriction endonuclease-
qPCR (MSRE-qPCR), and bisulfite genomic sequencing. Some
methylation assays used a real-time PCR–SYBR Green approach to
detect methylated and unmethylated DNA; however, the percen-
tage of methylation is not truly quantified unless methylation and
unmethylation control standards are included. Therefore, we
considered those assays to be N-MSP. MSRE-qPCR uses a different
approach from Q-MSP. It targets the non-bisulfite converted DNA
sequence by methylation-sensitive/insensitive endonuclease with-
out using primers specific for methylated and unmethylated
sequences; therefore, it is not considered to be Q-MSP in the
current manuscript.
As shown in Table 1, 12 studies (Cairns et al, 2001; Goessl et al,
2001a,b; Jeronimo et al, 2002; Gonzalgo et al, 2003, 2004; Crocitto
et al, 2004; Rogers et al, 2006; Reibenwein et al, 2007; Altimari
et al, 2008; Roupret et al, 2008; Sunami et al, 2009) used N-MSP
and the same set of methylated/unmethylated primers (B74 to
170nt) to target the same CpG dinucleotides. Among those using
Q-MSP (Chuang et al, 2007; Bastian et al, 2008; Bryzgunova et al,
2008; Ellinger et al, 2008), two targeted the region ‘29–168nt’, one
targeted ‘179–305nt’, and one ‘7–122nt’. Bastian (2008), Bryzgu-
nova (2008), Chuang (2007), and Ellinger (2008) used MSRE-qPCR
or bisulfite sequencing to investigate the methylation status of CpG
dinucleotides at the GSTP1 promoter. Although the sequence of
primers in these studies (Chuang et al, 2007; Bastian et al, 2008;
Bryzgunova et al, 2008; Ellinger et al, 2008) did not fall in the ‘þ74
to 170 nt’ or ‘þ7 to 305 nt’ regions, they were all located at the
50 promoter region of GSTP1 ( 80 to 400nt from its transcrip-
tional start site).
For our stratified analyses, we classified methylation methods
based on their primer sequence, location, and PCR method. We
categorised studies using N-MSP as one group and studies using
Q-MSP, MSRE-qPCR, or bisulfite sequencing (plus one study
Medline
78
References from
papers
24 
22 studies 
Exclude
Review paper (12) 
Not related to prostate cancer (8) 
Repeated publications from the same study (10) 
No raw data available or cannot further retrieve any 
raw data from previous authors (6) 
Exclude same paper from both searching tools (44)
58 studies 
Figure 1 Flow diagram for the selection of studies.
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s(Papadopoulou et al, 2006) using gene scan) as another group,
because there are not enough sample sizes to further stratify the
second group by individual methylation methods.
Among the 22 studies, 11 studies used plasma or serum (Goessl
et al, 2001a; Jeronimo et al, 2002; Papadopoulou et al, 2006;
Chuang et al, 2007; Reibenwein et al, 2007; Altimari et al, 2008;
Bastian et al, 2008; Bryzgunova et al, 2008; Ellinger et al, 2008;
Sunami et al, 2009), and 11 studies used urine (Cairns et al, 2001;
Goessl et al, 2001a,b; Jeronimo et al, 2002; Gonzalgo et al, 2003,
2004; Hoque et al, 2005; Rogers et al, 2006; Roupret et al, 2007;
Bryzgunova et al, 2008; Woodson et al, 2008; Payne et al, 2009),
1 study used whole blood (Roupret et al, 2008), 2 studies used
ejaculates (Suh et al, 2000; Goessl et al, 2001a), and 2 studies used
prostate secretions (Crocitto et al, 2004; Gonzalgo et al, 2004).
Some studies collected more than one type of biospecimen.
Data extraction
Using a standardised data extraction form, two independent
investigators (TW and PM) extracted and tabulated all data.
Discrepancies were resolved by discussions with other co-authors.
We included the author’s last name, year of publication, sample
size, mean subject age, cancer clinical classification, type of PCR
method, and other relevant characteristics of the study population.
We extracted the number of positive and negative results among
cases and controls. Specifically, the primer location, sequence, and
PCR method in each study are summarised in Table 1.
Statistical analysis
Pooled specificity and sensitivity Sensitivity and specificity
estimates from each study were analysed using random-effects
models. To assess whether variation in the threshold definition of a
positive result produced an association between sensitivity and
specificity values across studies, we needed to establish whether
there was an association between these parameters. The summary
receiving operating characteristic (S-ROC) curve describes the
extent of this relationship (Midgette et al, 1993). The S-ROC was
obtained by estimating the linear regression of the log-odds ratio
from each study on the sum of the logits of the true-positive and
false-positive rates. When the regression between these quantities
is null, independent analyses of pooled sensitivity and specificity
using standard methods for binary data are appropriate. In these
cases, data were analysed on the log-odds scale (e.g., for
specificities, the effect size used was log(Spec/(1-Spec)), with
approximate variance (1/R) þ (1/(N-R)), where N and R are the
number of negative (control) cases and the number of false
positives, respectively, in the study. A continuity correction of 0.5
was added to each cell to allow calculations in the presence of zero
cell counts.
Table 1 Summary of primer sequences used in methylation study of GSTP1
Primers sequences*
Groups Methods
Primers
location
CG’s
location Forward Reverse
Altimari
et al, 2008
N-MSP
a +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP
a +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Bastian
et al, 2008
MSRE-qPCR
b  4 to +256 +243 5’-GAC CTG GGA AAG AGG GAA AG-3’ 5’-ACT CAC TGG TGG CGA AGA CT-3’
Bryzgunova
et al, 2008
BS
c  4 to +388 43 CpG sites 5’-GAT TTG GGA AAG AGG GAA AGG-3’ 5’-CTA AAA ACT CTA AAC CCC ATC C-3’
Cairns et al,
2001
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGC TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Chuang
et al,
2007
MSRE-qPCR
b  48 to +259  48, +243,
+259
5’-CGG TCC TCT TCC TGC TGT CT-3’ 5’-CGT ACT CAC TGG TGG CGA AG-3’
Crocitto
et al, 2004
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Ellinger
et al,
2008
MSRE-qPCR
b +123 to 259 +243 5’-GGG ACC CTC CAG AAG AGC-3’ 5’-ACT CAC TGG TGG CGA AGA CT-3’
Goessl et al,
2001a
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Goessl et al,
2001b
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Gonzalgo
et al, 2004
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-AGT TGC GCG GCG ATT TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Gonzalgo
et al, 2003
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Hoque
et al, 2005
Q-MSP^ +29 to 168 +34, 36, 39, 45,
147, 150, 168
M 5’-AGT TGC GCG GCG ATT TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Probe 6FAM CGG TCG ACG TTC GGG GTG TAG CG-TAMRA
Jeronimo
et al, 2002
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Papadopoulou
et al, 2006
NA NA
(gene scan)
NA
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sCGGTCCTCTTCCTGCTGTCTGTTTACTCCCTAGGCCCCGCTGGGGACC
CGGCCAGCTGCGCGGCGACTCCGGGGA
CGCCCCTCTGCGGCCGACGCCCGGGGTGCAGCGGCCGCCGGG
CCGGCGGGAGTCCGCGGGACCCTCCAGAAGAGCGGCCGGCGCC
GTGACTCAGCACTGGGGCGGAGCGGGGCGGGACCACCCTTATAAGGCTCG
CGCGAGGCCTTCGCTGGAGTTTCGCCGCCGCAGTCTTCGCCACCA
GTGAGTACGCGCGGCCCGCGTCCCCGGGGATGGGGCTCAGAGCTCCCAGC
ATGGGGCCAACCCGCAGCATCAGGCCCGGGCTCCCGGCAGGGCTCCTCGC
CGAGACCCGGGACGGGGGCCTAGGGGACCCAGGACGTCCCCAGT
–100 AATTTCCCCCCGCGATGTCCCGGCGCGCCAGTTCGCTGCGCACACTTCGC 
–50 TG
+1 TGGGAAAGAGGGAAAGGCTTCCC
+51 CTCCAGGG
+101 GCTGGGG
+151
+201 GAGGC
+251
+301
+351 CCACCT
+401 GCCGTTAGCGGCTTTCAGGGGGCCCGGAGCGCCTCGGGGAGGGATGGGAC
TSS
Remarks:
NCBI Reference Sequence: NG_012075.1 (4900 to 5450).
TSS: Transcription start site (+1). 
Yellow: primers for non-quantitative methylation specific PCR (N-MSP).
Underline: primers for quantitative methylation specific PCR (Q-MSP).
Pink: primers for bisulphite genomic sequencing (BS).
Gray: primers for methylation sensitive restriction endonuclease-qPCR (MSRE-qPCR).
Bold and italic: reverse primers.
Red: CG are highlighted in red.
Table 1 (Continued)
Primers sequences*
Groups Methods
Primers
location
CG’s
location Forward Reverse
Payne et al,
2009
Q-MSP +179 to 305 +228, 230, 232,
243
M 5’-GGG ATT ATT TTT ATA AGG TT-3’ 5’-CCC ATA CTA AAA ACT CTA AAC-3’
Probe 5’-AGT TTC GTC GTC GTA GTT TTC GTT-FL
Blockers 5’-CTA AAC CCC ATC CCC AAA AAC ACA AAC CAC ACA-Cy3
LC- RAD- TAG TGA GTA CGC GCG GTT CG-PH
Reibenwein
et al, 2007
N-MSP Not
published
NA
Rogers et al,
2006
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
+78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Roupret
et al, 2008
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Roupret
et al, 2007
Q-MSP +29 to 168 +34, 36, 39, 45,
147, 150, 168
M 5’-AGT TGC GCG GCG ATT TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Probe 6FAM CGG TCG ACG TTC GGG GTG TAG CG-TAMRA
Suh et al,
2000
MSRE-qPCR
b +1 to 164 150 5’-TGG GAA AGA GGG AAA G-3’ 5’-CAG TGC TGA GTC GC-3’
Sunami
et al, 2009
N-MSP +74 to 170 +80, 90, 94,
147, 150, 168
U 5’-GAT GTT TGG GGT GTA GTG GTT GTT-3’ 5’-CCA CCC CAA TAC TAA ATC ACA ACA-3’
N-MSP +78 to 168 +80, 90, 94,
147, 150, 168
M 5’-TTC GGG GTG TAG CGG TCG TC-3’ 5’-GCC CCA ATA CTA AAT CAC GAC G-3’
Woodson
et al, 2008
Q-MSP +7 to 122 +109, 112, 120 M 5’-AGA GGG AAA GGT TTT TTC GGT T-3’ 5’-GCG AAC TCC CGC CGA-3’
Probe 6FAM TGC GCG GCG ATT TCG GG-TAMRA
Note: For Q-MSP, N-MSP and BS, DNA samples are bisulphite-treated prior to PCR. Unmethylated Cytosine (C) is converted to Thymine (T) while methylated-C is protected from
bisulphite treatment. ^Q-MSP¼quantitative methylation specific PCR. Primers are designed specific for methylated and unmethylated sequences, respectively. An internal probe is included
in real-time PCR assay. Methylation % is quantitatively measured with a methylated DNA control standard.
aN-MSP¼non-quantitative methylation specific PCR. Primers are designed specific
for methylated and unmethylated sequences.
bMSRE-qPCR¼Methylation Sensitive Restriction Endonuclease-qPCR. Primers are designed for non-bisulphite converted DNA sequence.
DNA is digested with methylation sensitive restriction endonuclease prior to PCR.
cBS¼bisulphite genomic sequencing. Primers are designed at region without any CpG. NA¼Not
applicable. *Sequence analysis of GSTP1 is based on NCBI Reference Sequence: NG_012075.1 A total of 43 CpG dinucleotides locating at 50 promoter region ( 80 to +400nt).
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(based on deviations of observed log-odds from the common log-
odds under a fixed-effect model) was also performed for each
analysis.
All analyses were performed using the MIXED procedure in SAS
version 9.2. In particular, we observed significant heterogeneity
among study outcomes (variation beyond chance expectation),
which can complicate the interpretation of findings. However, this
is rarely a valid reason for abandoning a meta-analysis altogether.
Heterogeneity indicates that a single estimate for the parameter(s)
of interest does not hold over all conditions that have been studied
and that exploration of which conditions are associated with such
variation is warranted. A meta-regression can be used to verify
whether any suspected factors may contribute to this hetero-
geneity. We conducted a meta-regression to examine whether the
specificity or sensitivity may be predicted by any of the following
factors: age, methylation method, and sample type.
Pooled odds ratio (OR)among cases: Methylation associated with
pathological stage, Gleason score, and PSA levels We found that
the sensitivity of GSTP1 promoter methylation varied considerably
among the studies. We applied the random-effect model to directly
analyse the pooled odds ratios of methylation associated with
pathological stage, Gleason score, and PSA levels. We adjusted for
age, sample type, and methylation method; if none of them
appeared to be significant in the model, these variables were
removed from the model. Our analyses were limited to samples
collected prior to treatment.
RESULTS
Individual specificity and pooled specificity of GSTP1
promoter methylation in all studies and in studies using
different types of samples
Negative-biopsy controls (16 studies) are shown in Table 2. Most
of the GSTP1 specificities were high and above 0.5, although the
GSTP1 specificity in one study was below 0.5. The pooled
specificity (Table 3) was 0.89 (95% CI, 0.80–0.95), suggesting that
the GSTP1 methylation test has a much higher specificity than the
PSA test. The P-value for heterogeneity was o0.001, indicating
significant heterogeneity. Moreover, we performed stratified
analyses on the studies according to sample type (plasma/serum
or urine) and methylation method (N-MSP or other methods), as
shown in Table 3. The specificity was similar between plasma/
serum and urine samples regardless of methylation method. Four
studies used biospecimens other than plasma/serum or urine. As
the sample sizes from these studies were too small to further
stratify by methylation method or location of primer, we analysed
the pooled specificity of these four studies. The pooled specificity
Table 2 Specificity from each individual study using only negative biopsies as controls
a
Study (15 studies) Specimen type
Methylation
method Control type
No. of
negatives
No. of total
controls Specificity
Altimari et al, 2008 Plasma N-MSP BPH 4 5 0.80
Bastian et al, 2008 Serum MSRE-qPCR No special diagnosis
b 35 35 1.00
Bryzgunova et al, 2008 Serum BS BPH 5 5 1.00
Urine BS BPH 5 5 1.00
Chuang et al, 2007 Plasma MSRE-qPCR BPH 25 27 0.93
Crocitto et al, 2004 Prostate secretions N-MSP No special diagnosis 19 34 0.56
Ellinger et al, 2008 Serum MSRE-qPCR BPH 39 42 0.93
Goessl et al, 2001a Buffy coat N-MSP BPH 26 26 1.00
Serum N-MSP BPH 22 22 1.00
Ejaculate N-MSP BPH 6 6 1.00
Urine N-MSP BPH 10 10 1.00
Goessl et al, 2001b Urine (after massage) N-MSP BPH 44 45 0.98
Gonzalgo et al, 2003 Urine N-MSP No special diagnosis 11 18 0.61
Jeronimo et al, 2002 Urine N-MSP BPH 30 31 0.97
Plasma N-MSP BPH 31 31 1.00
Urine N-MSP BPH 30 31 0.97
Plasma N-MSP BPH 31 31 1.00
Payne et al, 2009 Plasma Q-MSP No special diagnosis 35 51 0.69
Urine (after massage) Q-MSP No special diagnosis 21 51 0.41
Rogers et al, 2006 Urine after rectal N-MSP No special diagnosis 4 5 0.80
Urine after biopsy N-MSP No special diagnosis 4 5 0.80
Roupret et al, 2007 Urine (after message) Q-MSP No special diagnosis and BPH 33 38 0.87
Roupret et al, 2008 Blood N-MSP No special diagnosis 20 22 0.91
Woodson et al, 2008 Urine (after massage) Q-MSP BPH 68 69 0.99
Abbreviations: BPH¼benign prostate hyperplasia; BS¼bisulphite genomic sequencing; N-MSP¼non-quantitative methylation specific PCR; Q-MSP¼quantitative methylation
specific PCR; SRE-qPCR¼methylation sensitive restriction endonuclease-qPCR.
aWe did not ininclude Hoque et al, 2005 in which 25 female do not have a prostate biopsy and
25 patients may be healthy.
bPatients with negative biopsies but no special diagnosis.
Table 3 Specificity of GSTP1 methylation test in plasma and urine samples
Number of studies Specimen type Methylation method Pooled specificity 95%CI P-value for heterogeneity
3 Plasma/serum N-MSP
a 0.96 0.78–0.99 Po0.001
5 Plasma/serum Other methods
b 0.90 0.74–0.96 Po0.001
5 Urine N-MSP 0.90 0.70–0.97 Po0.001
4 Urine Other methods
b 0.86 0.47–0.98 Po0.001
Pooled specificity 0.89 0.80–0.95 Po0.001
aN-MSP¼non-quantitative methylation specific PCR.
bOther methods include quantitative methylation specific PCR, methylation sensitive restriction endonuclease-qPCR, and
bisulphite genomic sequencing.
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swas 0.85 (95% CI, 0.48–0.97)(data not shown). The P-value for
heterogeneity in each stratum was significant (Table 3).
Meta-regression analyses indicated a nonsignificant inverse
association between age and specificity (b estimate¼ 0.22;
P¼0.2). No significant associations were observed between
specificity and methylation method or between specificity and
sample type.
Finally, the pooled specificity among the studies using healthy
controls was high (0.92; 95% CI, 0.81–97), regardless of
methylation method and sample type. The P-value for hetero-
geneity was 0.07, suggesting that there may still be variation not
attributable to these covariates.
Individual and pooled sensitivity of GSTP1 promoter
methylation
Unlike the relatively high specificity of GSTP1 found among most
studies, the sensitivity of GSTP1 varied widely, from 0.05 to 1
(Supplementary Table 2, online only). The overall pooled
sensitivity was 0.52 (95% CI, 0.40–0.64) (Table 4). No particular
trend was observed among these studies in regard to methylation
method or type of specimen (Table 4). The estimated pooled
sensitivity for other types of specimens (ejaculate, prostate
secretion, and others) was 0.66 (95% CI, 0.35–0.85). As only six
studies used other types of specimens, we did not further stratify
them by methylation method. The heterogeneity test P-values for
the overall pooled sensitivity and the individual pooled sensitivity
in each stratum were significant.
Upon further exploration, we found that sensitivity was higher
in untreated samples (0.63; 95% CI, 0.50–0.75) than in treated
samples (0.40; 95% CI, 0.25–0.78), regardless of the specimen type
and the methylation method (Table 4). Further stratification by
specimen type and methylation method among the treated and
untreated groups revealed a higher sensitivity among the untreated
(Table 5).
Meta-regression did not reveal any significant associations between
sensitivity and age, between sensitivity and methylation method, or
between sensitivity and sample type, but the meta-regression did
show that sensitivity was significantly lower in the treated samples
than in the untreated samples (beta¼ 1.22, P¼0.02).
GSTP1 promoter methylation in relation to pathological
stage, Gleason score, and PSA levels among prostate
cancer cases
To further evaluate the odds ratios, we converted the pathological
stage from an ordinal variable to a binary variable, that is, stages
3–4vs 1–2. Likewise, we categorised Gleason scores as higher than
7 or lower than 7 and grouped PSA levels into higher or lower than
4ngml
 1. We limited our analyses to untreated samples and
adjusted for methylation method and age; however, if any variable
was not significant, it was removed from the model.
Six studies (Goessl et al, 2001b; Hoque et al, 2005; Ellinger et al,
2008; Roupret et al, 2008; Woodson et al, 2008; Payne et al, 2009)
and additional unpublished data (provided Drs Roupret and James
Catto) had sufficient information for analysing the association
between gene methylation and pathological stage. We found that
GSTP1 promoter methylation increased with prostate cancer
pathological stage (stages 3–4 vs 1–2), with an odds ratio of
1.66 (95% CI, 0.86–3.19). The P-value for heterogeneity was 0.2
(Figure 2). We adjusted for age, sample type, and methylation
method in the model; however, as none of these variables were
significant, they were removed from the final model. When we
excluded the study that used whole blood samples (Roupret et al,
2008), the odds ratio slightly increased (OR¼1.80; 95% CI,
0.88–3.68; P for heterogeneity¼0.2).
For similar reasons, we did not adjust for age, methylation
method, or sample type for the following analyses. We found that
GSTP1 promoter methylation was not associated with Gleason
Table 5 Sensitivity of GST-P1 methylation test stratified by treated and untreated samples
Treated
a
Number of studies Specimen type PCR method/sequence location Pooled sensitivity 95%CI P for heterogeneity
3 Plasma N-MSP
b 0.32 0.13–0.60 o0.001
3 Plasma Other methods
c 0.25 0.13–0.41 o0.001
3 Urine N-MSP 0.42 0.15–0.75 o0.001
1 Urine Other methods NA NA NA
Untreated
1 Plasma N-MSP NA NA NA
4 Plasma Other methods 0.53 0.32–0.73 o0.001
3 Urine N-MSP 0.49 0.22–0.77 o0.001
4 Urine Other methods 0.72 0.50–0.86 o0.001
aTreated or untreated: represents that the samples were collected either after treatments or before treatments.
bN-MSP¼non-quantitative methylation specific PCR.
cOther
methods: quantitative methylation specific PCR, methylation sensitive restriction endonuclease-qPCR, and bisulphite genomic sequencing.
Table 4 Sensitivity of GST-P1 methylation test
Number of studies Specimen type PCR method/sequence location Pooled sensitivity 95%CI P for heterogeneity
5 Plasma N-MSP
a 0.42 0.18–0.71 o0.001
6 Plasma Other methods
b 0.36 0.23–0.52 o0.001
6 Urine N-MSP 0.45 0.25–0.66 o0.001
5 Urine Other methods 0.75 0.58–0.86 o0.001
11 Treated
c NA 0.40 0.25–0.58 o0.001
12 Untreated
c NA 0.63 0.50–0.75 o0.001
Pooled sensitivity 0.52 0.40–0.64 o0.001
aN-MSP¼non-quantitative methylation specific PCR.
bOther methods: quantitative methylation specific PCR, methylation sensitive restriction endonuclease-qPCR, and
bisulphite genomic sequencing.
cTreated or untreated: represents that the samples were collected either after treatments or before treatments.
GSTP1 promoter methylation test may complement PSA screening
TW uet al
70
British Journal of Cancer (2011) 105(1), 65–73 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
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heterogeneity¼0.4; 5 studies) (Goessl et al, 2001b; Hoque et al,
2005; Ellinger et al, 2008; Roupret et al, 2008; Woodson et al,
2008)(additional unpublished data provided by Drs Roupret and
James Catto). Furthermore, GSTP1 promoter methylation was not
associated with high-PSA levels (odds ratio¼0.93, 95% CI, 0.77–1.02;
P-value for heterogeneity¼0.1; 5 studies)(Gonzalgo et al, 2004;
Hoque et al, 2005; Rogers et al, 2006; Roupret et al, 2007; Woodson
et al, 2008).
DISCUSSION
The pooled specificity of GSTP1 was excellent (0. 89, 95% CI,
0.80–0.95) and much higher than the specificity of PSA. The
specificity in each subgroup (stratified by sample type and
methylation method) remained above 0.86. The sensitivity of
GSTP1 was 0.63 (95% CI, 0.50–0.75) for samples collected before
treatment and 0.40 (95% CI, 0.25–0.78) for samples collected after
treatment; these sensitivities were not higher than the sensitivity of
PSA screening. These results suggest that plasma, serum, or urine
samples may complement PSA screening for prostate cancer
diagnosis, although the positive link between GSTP1 methylation
and pathological stage needs to be evaluated in more studies.
Collecting plasma/serum or urine samples is a non-invasive
procedure, whereas invasive biopsy procedures may cause pain,
anxiety, and increased medical costs. Urine samples were voided
urine except the urine samples collected in the following studies:
four were collected after a massage (Goessl et al, 2001b; Rogers
et al, 2006; Woodson et al, 2008; Payne et al, 2009) and one after a
biopsy (Rogers et al, 2006). High specificity remained even after we
excluded the studies with urine collection after a massage.
This study highlights several important issues. First, we
identified and systemically evaluated the methylation test at the
GSTP1 promoter as an important potential test to complement
PSA screening. As a complement rather than a replacement for
PSA is needed, a high specificity is more important than a high
sensitivity. To combine the strengths of both tests, they should be
used sequentially, not simultaneously. The PSA test will be initially
used to screen out potential patients, and the GSTP1 methylation
test will then be given to those patients who have elevated PSA
levels. Only those who have elevated PSA levels, followed by
positive results on the GSTP1 methylation test, will undergo
further biopsies. With its high specificity, the methylation test will
exclude patients unlikely to have PCa but have elevated PSA levels.
Using the two tests sequentially will reduce the number of
unnecessary biopsies considerably, compared with using the PSA
test alone. Serial testing has been used clinically for embolism and
diarrhea (Fekety, 1997; Wells et al, 2001).
Second, unlike previous studies and reviews, we rigorously
evaluated the specificity of GSTP1 by excluding healthy controls.
In epidemiological research, we use controls that represent the
population from which the cases were derived. As described above,
randomly selected healthy controls usually do not have elevated
levels of PSA or abnormal urological symptoms; therefore, they
cannot represent patients who have high levels of PSA and undergo
biopsy tests. Third, no previous studies have systemically
evaluated the diagnostic value of measuring GSTP1 promoter
methylation in different types of body fluids for prostate cancer
diagnosis. This study indicates that the use of plasma/serum or
urine samples for prostate cancer diagnosis is an important, non-
invasive procedure that can complement PSA screening and
minimise unnecessary biopsies.
Future assays that measure DNA methylation at gene promoters
need to be standardised, simplified, and evaluated with external
quality assurance programmes. Quantitative methods, such as
pyrosequencing (o200bp) and MassArrays (o600bp), which
truly quantify all the DNA methylation in the CpG islands and
measure levels of all CpG dinucleotides, are also high-throughput
technologies. Therefore, pyrosequencing and MassArrays are
considered to be more efficient for validating the DNA methylation
of gene promoters.
Of note, Figure 2 indicates that the DNA methylation test in
whole blood samples is less sensitive to prostate cancer stages than
the same test done in plasma, serum, or urine (Roupret et al,
2008). The methylated DNA in plasma, serum, or urine most likely
derives from cancer cells whereas the methylated DNA detected in
whole blood can be released from white blood cells as well.
Therefore, the DNA methylation test in plasma, serum, or urine may
be more accurate than the same test applied to whole blood in
reflecting the severity of cancer stage. As most prostate cancer cases
are detected at an early stage, the current PSA test does not predict
specific prostate cancer stages. If GSTP1 methylation in plasma,
serum, or urine samples is associated with pathological stage, this
test will be even more appealing in addition to its high-specificity
feature. More studies are warranted to confirm this finding.
Odds ratio
0.1 1 10
Study – % Weight Odds ratio
(95% CI)
1.16 (0.61 2.21) Ellinger et al, 2008-serum 36.1
1.63 (0.39 6.81) Goessl et al, 2001-urine 15.2
0.87 (0.29 2.58) Hoque et al, 2005-urine 21.8
4.48 (1.04 19.37) Payne et al, 2009-plasma 14.7
8.46 (0.47 150.81) Payne et al, 2009-urine 4.7
0.58 (0.03 13.11) Roupret et al, 2008-blood 4.1
27.00 (0.85 856.53) Woodson et al, 2008-urine 3.4
1.66 (0.86 3.19) Overall (95% CI)
P-value for heterogeneity = 0.2 
Figure 2 GSTP1 methylation in body fluids collected before treatment and risk of advanced stage of prostate cancer (comparing pathological stages 3–4
to stages 1–2). P-value for heterogeneity¼0.2.
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assay of gene promoter methylation used in each study was
different; some used N-MSP, others used Q-MSP, MSRE-Qpcr, or
bisulfite sequencing, adding additional heterogeneity. Gonzalgo
et al, 2004 (Gonzalgo et al, 2004) commented that primers selected
at different regions on the same CpG island may have different
sensitivities and specificities. Fortunately, the studies included in
this paper all chose primers targeting the CpG dinucleotides in the
50 promoter region starting from  80 to 400nt from its
transcriptional start site; hence findings in these studies are still
believed to be appropriate for our analyses, as DNA methylation
mostly occurs at the 50 promoter region. Nevertheless, the
specificity of GSTP1 across different methylation methods was
consistently higher than the specificity of PSA, even though a wide
range of sensitivities for GSTP1 was noted. This indicates the
robustness of specificity of the GSTP1 methylation assay.
Furthermore, our study did not find an association between
sensitivity or specificity and methylation method.
Second, only 15 studies that did not use healthy controls could
be used for specificity calculations. However, some of these studies
used more than one specimen and gave us additional statistical
power. Nevertheless, the evidence is compelling, in that the
majority of individual GSTP1 specificities calculated here were
higher than 0.8, and the overall pooled specificity was 0.89.
Third, the sample collection time varied widely among the studies.
As mentioned above, because of our concern over the influence of
treatment, we limited our analysis to untreated cases when analysing
the associations between gene methylation and pathological stage
and other factors, thereby decreasing our statistical power.
In summary, we summarised primer sequences, nucleotide
position, and PCR methods in each study and evaluated them
using a meta-analysis, which is a unique approach compared with
a traditional review without any statistical analyses. Our study
represents a new trend in epidemiology: a cross-disciplinary
approach between molecular biology and epidemiology. Measuring
DNA methylation at gene promoters has the potential to provide a
new generation of biomarkers for prostate cancer diagnosis.
Future studies should focus on the following tasks: (1) standardis-
ing the primers and the PCR protocols for each target gene;
(2) using plasma, serum, or urine samples; (3) using patients with
negative biopsies as controls rather than randomly selected healthy
controls; and (4) collecting samples from cases before biopsies or
at least before treatment to improve sensitivity. These tasks will
reduce the heterogeneity among studies, enabling us to conduct an
accurate meta-analysis to find a complement for the PSA test.
Finally, more studies are needed to examine the association
between gene methylation status and the stage and prognosis of
prostate cancer. This will help avoid unnecessary treatment of
some localised prostate cancers, as prostate cancer therapies are
associated with significant adverse effects that impact patients’
health and quality of life.
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